PL2020996T3 - Sposób i kompozycje do leczenia chorób nowotworowych układu krwiotwórczego - Google Patents

Sposób i kompozycje do leczenia chorób nowotworowych układu krwiotwórczego

Info

Publication number: PL2020996T3
Authority: PL; Poland
Prior art keywords: hematological malignancies; compositions; treating hematological; compound; salt
Prior art date: 2006-05-16

Application number

PL07794933T

Other languages

English (en)

Inventor

Lee S Chong

William A Lee

Adrian S Ray

Hans C Reiser

Daniel B Tumas

William J Watkins

Original Assignee

Gilead Sciences Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-05-16

Filing date

2007-05-16

Publication date

2012-04-30

2007-05-16 Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc

2012-04-30 Publication of PL2020996T3 publication Critical patent/PL2020996T3/pl

Links

208000002250 Hematologic Neoplasms Diseases 0.000 title abstract 2
239000000203 mixture Substances 0.000 title 1
150000003839 salts Chemical class 0.000 abstract 2
206010028980 Neoplasm Diseases 0.000 abstract 1
150000001720 carbohydrates Chemical class 0.000 abstract 1
229940125904 compound 1 Drugs 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
-1 organic acid salt Chemical class 0.000 abstract 1
239000012453 solvate Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Biochemistry (AREA)
Public Health (AREA)
Molecular Biology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Oncology (AREA)
Hematology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Processing Of Solid Wastes (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

PL07794933T 2006-05-16 2007-05-16 Sposób i kompozycje do leczenia chorób nowotworowych układu krwiotwórczego PL2020996T3 (pl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US80098306P	2006-05-16	2006-05-16
US83180506P	2006-07-18	2006-07-18
PCT/US2007/011726 WO2007136650A2 (en)	2006-05-16	2007-05-16	Method and compositions for treating hematological malignancies
EP07794933A EP2020996B1 (en)	2006-05-16	2007-05-16	Method and compositions for treating hematological malignancies

Publications (1)

Publication Number	Publication Date
PL2020996T3 true PL2020996T3 (pl)	2012-04-30

Family

ID=38578698

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL07794933T PL2020996T3 (pl)	2006-05-16	2007-05-16	Sposób i kompozycje do leczenia chorób nowotworowych układu krwiotwórczego

Country Status (19)

Country	Link
US (3)	US20090258840A1 (pl)
EP (1)	EP2020996B1 (pl)
JP (2)	JP5544165B2 (pl)
KR (1)	KR101424832B1 (pl)
CN (1)	CN101442994B (pl)
AT (1)	ATE534377T1 (pl)
AU (1)	AU2007254309B2 (pl)
BR (1)	BRPI0711646C1 (pl)
CA (1)	CA2652048C (pl)
CY (1)	CY1112377T1 (pl)
DK (1)	DK2020996T3 (pl)
EA (1)	EA016995B1 (pl)
ES (1)	ES2377467T3 (pl)
MX (1)	MX2008014665A (pl)
NZ (1)	NZ572368A (pl)
PL (1)	PL2020996T3 (pl)
PT (1)	PT2020996E (pl)
SI (1)	SI2020996T1 (pl)
WO (1)	WO2007136650A2 (pl)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7407955B2 (en)	2002-08-21	2008-08-05	Boehringer Ingelheim Pharma Gmbh & Co., Kg	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en)	2004-02-18	2009-03-10	Boehringer Ingelheim International Gmbh	8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de)	2004-11-05	2006-05-11	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) *	2005-07-30	2007-02-08	Boehringer Ingelheim Pharma Gmbh & Co. Kg	8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
CN102838599A (zh)	2006-05-04	2012-12-26	贝林格尔.英格海姆国际有限公司	多晶型
PE20080251A1 (es)	2006-05-04	2008-04-25	Boehringer Ingelheim Int	Usos de inhibidores de dpp iv
EP1852108A1 (en)	2006-05-04	2007-11-07	Boehringer Ingelheim Pharma GmbH & Co.KG	DPP IV inhibitor formulations
KR101424832B1 (ko) *	2006-05-16	2014-08-06	길리애드 사이언시즈, 인코포레이티드	악성 혈액 종양 치료 방법 및 악성 혈액 종양 치료용 조성물
TWI444384B (zh)	2008-02-20	2014-07-11	Gilead Sciences Inc	核苷酸類似物及其在治療惡性腫瘤上的用途
PE20091730A1 (es)	2008-04-03	2009-12-10	Boehringer Ingelheim Int	Formulaciones que comprenden un inhibidor de dpp4
UY32030A (es)	2008-08-06	2010-03-26	Boehringer Ingelheim Int	"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR20200118243A (ko)	2008-08-06	2020-10-14	베링거 인겔하임 인터내셔날 게엠베하	메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
BRPI0919288A2 (pt)	2008-09-10	2015-12-15	Boehring Ingelheim Internat Gmbh	teriapia de combinação para tratamento de diabetes e condições relacionadas.
US20200155558A1 (en)	2018-11-20	2020-05-21	Boehringer Ingelheim International Gmbh	Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
EA022310B1 (ru)	2008-12-23	2015-12-30	Бёрингер Ингельхайм Интернациональ Гмбх	Солевые формы органического соединения
AR074990A1 (es)	2009-01-07	2011-03-02	Boehringer Ingelheim Int	Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
NZ599298A (en)	2009-11-27	2014-11-28	Boehringer Ingelheim Int	Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
WO2011138421A1 (en)	2010-05-05	2011-11-10	Boehringer Ingelheim International Gmbh	Combination therapy
NZ603319A (en)	2010-06-24	2015-04-24	Boehringer Ingelheim Int	Diabetes therapy
AR083878A1 (es)	2010-11-15	2013-03-27	Boehringer Ingelheim Int	Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
CA2841552C (en)	2011-07-15	2020-06-23	Boehringer Ingelheim International Gmbh	Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9555001B2 (en)	2012-03-07	2017-01-31	Boehringer Ingelheim International Gmbh	Pharmaceutical composition and uses thereof
US20130303554A1 (en)	2012-05-14	2013-11-14	Boehringer Ingelheim International Gmbh	Use of a dpp-4 inhibitor in sirs and/or sepsis
EP3685839A1 (en)	2012-05-14	2020-07-29	Boehringer Ingelheim International GmbH	Linagliptin for use in the treatment of albuminuria and kidney related diseases
WO2013174767A1 (en)	2012-05-24	2013-11-28	Boehringer Ingelheim International Gmbh	A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
CN103665043B (zh)	2012-08-30	2017-11-10	江苏豪森药业集团有限公司	一种替诺福韦前药及其在医药上的应用
ES2950384T3 (es)	2014-02-28	2023-10-09	Boehringer Ingelheim Int	Uso médico de un inhibidor de DPP-4
WO2017211979A1 (en)	2016-06-10	2017-12-14	Boehringer Ingelheim International Gmbh	Combinations of linagliptin and metformin
JP2021528363A (ja) *	2018-06-12	2021-10-21	シチュアンケルン−バイオテックバイオファーマシューティカルカンパニーリミテッド	ホスホンアミドエステル化合物、その塩、その関連する結晶体、その製造方法及びその使用
CN112168829B (zh) *	2020-09-24	2022-02-15	华南理工大学	抗病毒药物在制备治疗骨髓增生异常综合征药物中的应用及制得的骨髓增生异常综合征药物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5795909A (en) *	1996-05-22	1998-08-18	Neuromedica, Inc.	DHA-pharmaceutical agent conjugates of taxanes
CN1291994C (zh)	2000-07-21	2006-12-27	吉里德科学公司	核苷酸膦酸酯类似物前药及其筛选和制备方法
EP2319826A1 (en) *	2001-02-12	2011-05-11	Wyeth LLC	Succinate salt of O-desmethyl-venlafaxin
CA2468705A1 (en) *	2001-11-29	2003-06-05	Pfizer Products Inc.	Succinic acid salts of 5,8,14-triazatetracyclo'10.3.1.0<2,11>.0<4,9>-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof
AP2004003059A0 (en) *	2001-12-12	2004-06-30	Pfizer Prod Inc	Salt forms of E-2-methoxy-N-(3-(4-(3-methyl-pyridin-3-yloxyl)-phenylamino)-quinazolin-6-yl)-allyl)-acetamide, its preparation and its use against cancer
NZ536328A (en) *	2002-05-13	2007-11-30	Metabasis Therapeutics Inc	Novel phosphonic acid based prodrugs of PMEA and its analogues
US7563748B2 (en)	2003-06-23	2009-07-21	Cognis Ip Management Gmbh	Alcohol alkoxylate carriers for pesticide active ingredients
PL1658277T3 (pl) *	2003-08-18	2012-10-31	H Lundbeck As	Sól bursztynianowa i malonianowa trans-4-((1R,3S)-6-chloro-3-fenyloindan-1-ylo)-1,2,2-tri-metylopiperazyny i zastosowanie jako lek
HRP20100626T1 (hr) *	2003-12-30	2011-03-31	Gilead Sciences	Fosfonati, monofosfonamidati, bisfosfonamidati za liječenje virusnih bolesti
US20050239753A1 (en)	2004-01-21	2005-10-27	Gilead Sciences, Inc.	Methods of inhibition of MMTV-like viruses
DE102005041860A1 (de) *	2005-09-02	2007-03-08	Schering Ag	Nanopartikulärer Einschluss- und Ladungskomplex für pharmazeutische Formulierungen
US20070149552A1 (en) *	2005-12-16	2007-06-28	Wyeth	Lyophilized compositions of a triazolopyrimidine compound
KR101424832B1 (ko) *	2006-05-16	2014-08-06	길리애드 사이언시즈, 인코포레이티드	악성 혈액 종양 치료 방법 및 악성 혈액 종양 치료용 조성물

2007
- 2007-05-16 KR KR1020087030561A patent/KR101424832B1/ko active Active
- 2007-05-16 WO PCT/US2007/011726 patent/WO2007136650A2/en not_active Ceased
- 2007-05-16 CN CN200780017637XA patent/CN101442994B/zh active Active
- 2007-05-16 DK DK07794933.7T patent/DK2020996T3/da active
- 2007-05-16 BR BRPI0711646A patent/BRPI0711646C1/pt active IP Right Grant
- 2007-05-16 AU AU2007254309A patent/AU2007254309B2/en active Active
- 2007-05-16 NZ NZ572368A patent/NZ572368A/en unknown
- 2007-05-16 US US12/298,987 patent/US20090258840A1/en not_active Abandoned
- 2007-05-16 MX MX2008014665A patent/MX2008014665A/es active IP Right Grant
- 2007-05-16 US US11/803,822 patent/US20080039427A1/en not_active Abandoned
- 2007-05-16 ES ES07794933T patent/ES2377467T3/es active Active
- 2007-05-16 PL PL07794933T patent/PL2020996T3/pl unknown
- 2007-05-16 EA EA200802333A patent/EA016995B1/ru unknown
- 2007-05-16 PT PT07794933T patent/PT2020996E/pt unknown
- 2007-05-16 AT AT07794933T patent/ATE534377T1/de active
- 2007-05-16 SI SI200730862T patent/SI2020996T1/sl unknown
- 2007-05-16 CA CA2652048A patent/CA2652048C/en active Active
- 2007-05-16 JP JP2009511052A patent/JP5544165B2/ja active Active
- 2007-05-16 EP EP07794933A patent/EP2020996B1/en active Active
2011
- 2011-03-23 US US13/070,179 patent/US8435969B2/en active Active
2012
- 2012-02-16 CY CY20121100159T patent/CY1112377T1/el unknown
2013
- 2013-01-17 JP JP2013006055A patent/JP2013100324A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
KR20090015122A (ko)	2009-02-11
CN101442994A (zh)	2009-05-27
US20080039427A1 (en)	2008-02-14
CY1112377T1 (el)	2015-12-09
EA200802333A1 (ru)	2009-04-28
BRPI0711646A2 (pt)	2011-11-29
DK2020996T3 (da)	2012-02-27
HK1127913A1 (en)	2009-10-09
WO2007136650A3 (en)	2008-01-24
US20110172192A1 (en)	2011-07-14
CA2652048A1 (en)	2007-11-29
ATE534377T1 (de)	2011-12-15
SI2020996T1 (sl)	2012-03-30
KR101424832B1 (ko)	2014-08-06
CN101442994B (zh)	2013-03-06
PT2020996E (pt)	2012-02-20
WO2007136650A2 (en)	2007-11-29
BRPI0711646B8 (pt)	2021-04-06
BRPI0711646B1 (pt)	2020-12-01
AU2007254309B2 (en)	2012-05-03
JP2009537539A (ja)	2009-10-29
BRPI0711646C1 (pt)	2021-05-25
ES2377467T3 (es)	2012-03-27
EP2020996A2 (en)	2009-02-11
JP5544165B2 (ja)	2014-07-09
NZ572368A (en)	2011-04-29
US8435969B2 (en)	2013-05-07
EA016995B1 (ru)	2012-09-28
EP2020996B1 (en)	2011-11-23
JP2013100324A (ja)	2013-05-23
AU2007254309A1 (en)	2007-11-29
CA2652048C (en)	2012-12-11
MX2008014665A (es)	2008-11-28
US20090258840A1 (en)	2009-10-15

Publication	Publication Date	Title
SI2020996T1 (sl)	2012-03-30	Postopek in sestavki za zdravljenje hematološkihmalignosti
MY146111A (en)	2012-06-29	Acylaminopyrazoles as fgfr inhibitors
SG179418A1 (en)	2012-04-27	Inhibitors of the hedgehog pathway
TR201900306T4 (tr)	2019-02-21	Mek inhibitörlerini kullanma yöntemleri.
TN2009000400A1 (en)	2010-12-31	Methods of treating cancer using pyridopyrimidininone inhibitors of pi3k alpha
AP1913A (en)	2008-10-31	Substituted benzazoles and use thereof as raf kinase inhibitors
EA200600689A1 (ru)	2006-08-25	Замещённые бензазолы и их применение в качестве ингибиторов raf киназы
UA96777C2 (ru)	2011-12-12	Фенилпропионамидные соединения и их применение как опиоидных агонистов
MY150797A (en)	2014-02-28	Combination therapies comprising quinaxoline inhibitors of pi3k-alpha for use in the treatment of cancer
MX2009000657A (es)	2009-05-28	Composiciones y metodos para el tratamiento de mucositis.
SI1737451T1 (sl)	2011-10-28	Monocikliäśni heterocikli kot kinazni inhibitorji
TN2010000293A1 (en)	2011-11-11	Thiazole derivatives used as pi 3 kinase inhibitors
MX2009005934A (es)	2009-06-17	Compuestos organicos.
MY150460A (en)	2014-01-30	Smac peptidomimetics useful as iap inhibitors
MY155719A (en)	2015-11-30	2-benzylpyridazinone derivatives as met kinase inhibitors
ECSP109953A (es)	2010-03-31	Derivados de piridazinona
MX2009012708A (es)	2009-12-08	Derivados de piridazinona.
ES2531190T3 (es)	2015-03-11	Método para producir un compuesto de 4-oxoquinolina
MX2010010300A (es)	2010-10-26	Formas de sal de inhibidores del objetivo de rapamicina en mamiferos.
NO20065416L (no)	2006-11-24	Hemming av fremstillingen av biogene sulfider via kombinasjoner av biocide og metabolske inhibitorer
TW200745094A (en)	2007-12-16	ATM inhibitor
MX2010008226A (es)	2010-10-25	Derivados de difluorobifenilamida para el tratamiento de hipertension ocular.
MX2011007165A (es)	2011-08-04	Derivados de piridazinona.
UA101018C2 (ru)	2013-02-25	Пирролопиримидинкарбоксамиды
MX351555B (es)	2017-10-19	Formas solidas de inhibidor de girasa (r)-1-etil-3-[5-[2-(1-hidrox i-1-metil-etil)pirimidin-5-il]-7-(tetrahidrofuran-2-il)-1h-benzim idazol-2-il]urea.